NUSANO NEWS
Quantum and Nusano Collaborate to Advance North American Critical Mineral Refining
The following is a copy of a press release issued by Quantum Critical Metals. Click here to view the original press release on TheNewswire.VANCOUVER, B.C., Canada and...
Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration
Photo above: On Friday, March 8, 2024, representatives from Nusano and The Wasatch Group cut the ribbon on the Radiance Lab, a 5,000 square foot radiochemistry space that will develop radioisotope separation and purification processes for Nusano. (L-to-R) Howard...
Nusano to Participate in the B. Riley Securities Radiopharma Investor Conference
VALENCIA, Calif. – February 26, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced it will participate in a presentation and panel at the B. Riley Securities Radiopharma Investor Conference in New York City on...
Nusano Names Rohan Jain as Commercial General Manager
VALENCIA, Calif. – Jan. 22, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced Rohan Jain as its Commercial General Manager. Jain and his team will work with Nusano’s customers and prospects to assess their needs and...
Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics
EVENT REPLAY NOW AVAILABLE Recorded December 19, 2023Press release updated December 14, 2023 to include addition of Dr. OrozcoVALENCIA, Calif. – Dec. 12, 2023 – Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will...
Nusano to Participate in October Investor Conferences
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced that senior management will participate in the following investor conferences in October.
Video Replay: Unlocking the Next $20-30B Market Opportunity in Oncology: Radioisotope Production & Applications
With many now expecting radiopharmaceuticals to grow into a $20-30 billion market, investors are increasingly looking at the obstacles and opportunities for suppliers and drugmakers in this space. To advance these discussions, on Friday, May 12, 2023, Nusano and...
Nusano to Participate in Isotope and Radiopharmaceutical Conferences
Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, is participating in two conferences in July 2023.
Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development
Nusano and PharmaLogic will collaborate to advance the development of radiopharmaceuticals for diagnostic and therapeutic applications.
Nusano Announces In-House Stable Isotope Program Led by Renowned Physicist Sarko Cherekdjian
Nusano is creating an in-house stable isotope program to enhance the company’s medical radioisotope production capabilities and decrease dependence on foreign supply chains.
Nusano to Participate in the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.
BLOG Posts
MedicalXpress: Researchers develop new method of precisely targeting cancer lesions while protecting healthy tissues
From MedicalXpress: A team of researchers has developed a new method that suppresses the distribution of drugs to...
Case Study: Radioisotope supply challenges affecting prostate cancer treatment
Experts at the Dana-Farber Cancer Institute report patient treatments were delayed by three months due to low supply of 177Lu-PSMA-617.
Welsh Government seeks to create ‘global centre of excellence in nuclear medicine’
The Welsh Government is working to secure a stable supply of medical radioisotopes for United Kingdom citizens for decades to come.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates